Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia

Author： Gora-tybor Joanna   Blonski Jerzy Z.   Robak Tadeusz  

Publisher： Informa Healthcare

ISSN： 1466-1861

Source： Mediators of Inflammation, Vol.12, Iss.3, 2003-01, pp. : 167-171

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 11, 2015-11 ,pp. : 967-969

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ofatumumab‐based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3788-3796

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 2, 2018-02 ,pp. : E52-E54

John Wiley & Sons Inc

Access to resources Recommend Favorite

Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3805-3811

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients

By  

Oncology, Vol. 84, Iss. 2, 2012-11 ,pp. : 115-122

Karger

Access to resources Recommend Favorite